EPM2A Antikörper (Isoform 9) (Biotin)
-
- Target Alle EPM2A Antikörper anzeigen
- EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
-
Bindungsspezifität
- AA 1-331, Isoform 9
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser EPM2A Antikörper ist konjugiert mit Biotin
-
Applikation
- ELISA
- Kreuzreaktivität
- Human
- Aufreinigung
- >95%, Protein G purified
- Immunogen
- Recombinant Human Laforin, isoform 9 protein (1-331AA)
- Isotyp
- IgG
- Top Product
- Discover our top product EPM2A Primärantikörper
-
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibody
EPM2A Reaktivität: Human WB, ELISA Wirt: Maus Monoclonal 6C6 unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (C-Term) antibodyEPM2A Reaktivität: Human WB, IF, IHC (p), ICC Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331), (Isoform 9) antibodyEPM2A Reaktivität: Human WB, ELISA, IHC, IF Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 244-331) antibodyEPM2A Reaktivität: Human ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) antibodyEPM2A Reaktivität: Human, Ratte, Maus ELISA, IHC Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331) antibodyEPM2A Reaktivität: Human WB, IP Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 80-130) antibodyEPM2A Reaktivität: Human, Rind (Kuh) WB, IHC, IHC (p) Wirt: Kaninchen Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 101-199) antibodyEPM2A Reaktivität: Human WB, ELISA Wirt: Maus Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 1-331) antibodyEPM2A Reaktivität: Human WB Wirt: Maus Polyclonal unconjugated
anti-Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A) (AA 244-331) antibodyEPM2A Reaktivität: Human WB Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 - Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Target
- EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
- Andere Bezeichnung
- EPM2A (EPM2A Produkte)
- Synonyme
- TG-B antikoerper, Tg(TcraK,TcrbK)TG-BFlv antikoerper, EPM2 antikoerper, MELF antikoerper, laforin antikoerper, EPM2A, laforin glucan phosphatase antikoerper, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha antikoerper, EPM2A antikoerper, Epm2a antikoerper
- Hintergrund
-
Background: negative regulation of TOR signaling, positive regulation of macroautophagy
Aliases: EPM2ALaforin antibody, isoform 9 antibody
- UniProt
- B3EWF7
- Pathways
- Cellular Glucan Metabolic Process
-
